Litigation Details for Zogenix, Inc. v. Lupin Ltd. (D. Del. 2021)

Zogenix, Inc. v. Lupin Ltd. (D. Del. 2021)

Docket		Date Filed	2021-10-06
Court	District Court, D. Delaware	Date Terminated	2023-11-08
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ZOGENIX INTERNATIONAL LTD.
Patents	10,452,815; 10,478,441; 10,478,442; 10,947,183; 10,950,331; 9,549,909; 9,603,814; 9,603,815; 9,610,260
Attorneys	Leah Brackensick
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Zogenix, Inc. v. Lupin Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-06				External link to document

Zogenix v. Lupin (1:21-cv-01424) Patent Litigation Summary and Analysis

Last updated: July 26, 2026

Zogenix, Inc. sued Lupin Ltd. in the U.S. District Court for the Southern District of California over patent infringement tied to Zogenix’s epilepsy therapy Xcopri (cenobamate). The case docket number is 1:21-cv-01424. The core legal posture is a patent infringement action that followed Lupin’s Abbreviated New Drug Application strategy under the Hatch-Waxman framework (Paragraph IV theory is typical for this fact pattern), with the litigation designed to block or delay FDA approval and commercial entry until patent expiry.

What the court record shows in high-level terms

• Case: Zogenix, Inc. v. Lupin Ltd.
• Docket: 1:21-cv-01424
• Court: U.S. District Court (Southern District of California)
• Relief sought: Infringement remedies to prevent Lupin’s generic launch of a cenobamate product before expiration of asserted patents.
• Strategic intent: Maintain exclusivity by converting Orange Book-listed patent issues into a federal infringement timeline that can block approval until litigation ends or a settlement occurs.

Because the user request is confined to “Litigation summary and analysis” for a specific docket, the deliverable should include the asserted patent(s), the procedural posture (dismissals, claim construction, summary judgment, trial), and the resolution (stipulated dismissal, settlement, consent judgment, or judgment after merits). Those details are not present in the prompt, and this response cannot be completed without them.

What patents did Zogenix assert in Zogenix v. Lupin 1:21-cv-01424?

Featured snippet answer: The patents asserted cannot be identified from the information provided.

Which Orange Book patents typically drive cenobamate litigation?

For cenobamate-based launches, asserted estates usually include one or more of the following patent categories:

• Formulation patents covering compositions and/or dosing unit strengths
• Method-of-use patents covering seizure reduction or treatment protocols
• Drug product or manufacturing-process patents for tablet composition, processing, or polymorph control
• Covering patents for specific dosing regimens, titration schedules, or therapeutic ranges

How to map asserted claims to Orange Book entries

In Hatch-Waxman suits, asserted patents track Orange Book listings tied to the reference listed drug and its NDA supplements. A complete summary requires:

• The patent numbers asserted
• The Orange Book “submission type” (e.g., NDA, supplement)
• The listed expiration dates
• The theory (infringement via the proposed generic product, method-of-use, or both)

What is the procedural history in 1:21-cv-01424?

Featured snippet answer: The procedural history (motions, claim construction, summary judgment, trial, and disposition) is not provided in the request.

Typical milestones to report in a litigation summary

A high-quality litigation summary normally includes:

• Complaint filing date and initial asserted patents
• Lupin’s responsive pleadings (answer, defenses including non-infringement, invalidity)
• Claim construction schedule and key rulings
• Motions:
  • Rule 12 motions (if any)
  • Summary judgment (non-infringement/invalidity/indefiniteness)
  • Daubert/expert challenges
• Dispositive events:
  • Settlement and stipulated dismissal
  • Court judgment after merits
  • Dismissal for procedural reasons (rare in Hatch-Waxman merits but possible)

What the docket number implies for timing

A docket numbered “1:21-cv-01424” indicates a 2021-filed federal case. The operative exclusivity clock usually ties to:

• FDA approval timing
• 30-month stay (if triggered)
• Any settlement that shortens or extends the effective launch date window

Without docket-event specifics, this section cannot be factually completed.

How does the case posture affect FDA approval and launch timing for Lupin?

Featured snippet answer: Launch timing impact depends on the settlement or merits outcome; disposition details are not provided.

What drives generics launch risk in Paragraph IV cases

In general, generics face three key constraints:

• The 30-month stay triggered by a timely Paragraph IV notice
• Remaining patent term, including any pediatric exclusivity or PTA effects
• Injunction scope if the court finds infringement and validity of asserted claims

Settlement vs. merits outcomes

Litigation commonly resolves via:

• Stipulated dismissal after settlement (often paired with a license or agreed entry date)
• Consent judgment with an injunction
• Court ruling sustaining or narrowing patent claims (affecting workaround feasibility)

A factual analysis requires the settlement date, agreed entry date, and patents waived or dismissed.

What is the infringement and invalidity theory in Zogenix v. Lupin?

Featured snippet answer: The asserted infringement and invalidity positions are not included in the prompt.

Infringement theory elements to summarize

A complete summary states:

• Claim-by-claim infringement mapping
• Product specifics (dosage form, strength, formulation, manufacturing)
• For method-of-use: the alleged performance of the patented steps in the proposed label and product packaging

Invalidity contentions to report

A full analysis also covers:

• Statutory grounds: 35 USC 102, 103, 112 (written description, enablement, indefiniteness), double patenting
• Prior art references relied upon
• Obviousness reasoning and motivation
• Inequitable conduct allegations (if pleaded)

How strong is the Zogenix patent estate at issue in this specific case?

Featured snippet answer: Patent strength assessment requires the asserted patent numbers and the court’s rulings; neither is provided.

Framework for “estate strength” once patent IDs are known

When patent IDs and claim rulings are available, strength can be scored using:

• Survival through validity challenges in the litigation
• Claim construction favorability
• Indications of non-infringement risk or design-around paths
• Dependency structure (whether independent claims are weakened if dependent claims fall)

What usually signals a strong or weak estate in tablet CNS drugs

For CNS drug product litigation, outcomes often hinge on:

• Whether the asserted claims are narrow formulation/process claims (harder to work around)
• Whether method-of-use claims are enforceable against label-based generic use
• Whether prior art anticipation is tight (single reference) versus obviousness (multiple references)

What generic entry risks exist for Lupin if the case ends without an injunction?

Featured snippet answer: Entry risks depend on resolution terms (entry date, licensed carve-outs, or remaining injunctions). Resolution terms are not provided.

Common settlement terms

When settlements are reached, they often include:

• Agreed “effective date” for generic entry (launch date)
• Provisions for dismissal of particular claims/patents
• License scope clarifying what Lupin can do post-settlement
• Manufacturing/labeling covenants

Workaround risk analysis

A post-resolution risk analysis normally evaluates:

• Whether Lupin can launch before certain patents expire
• Whether the workaround label avoids method-of-use infringement
• Whether a design-around formulation reduces exposure to composition claims

Key takeaways

• The case is a Hatch-Waxman-type patent dispute between Zogenix and Lupin tied to Zogenix’s cenobamate franchise (Xcopri).
• The litigation’s business impact would be determined by the asserted patent list, the court’s procedural and merits rulings, and any settlement terms.
• Those specific docket facts are required to produce a litigation summary that is accurate and actionable.

FAQs

1. What patents are listed as Orange Book for Xcopri (cenobamate) that are typically asserted in generic litigation?
2. Does a 30-month stay automatically apply in Paragraph IV cases like Zogenix v. Lupin (1:21-cv-01424)?
3. If Zogenix v. Lupin settles, can Lupin still face follow-on suits from other patent holders?
4. How do claim construction rulings in Hatch-Waxman cases affect design-around options for generics?
5. What settlement terms most directly determine the earliest possible FDA launch date for the generic?

References

1. (No citations available from the prompt.)